In brief
- A Ghent team characterized four cyanazenes in cell assays of mu-opioid receptor activation, not their effects in people.
- They are nitazene-scaffold analogs with a cyano substitution. This review did not inspect Chinese legislation and does not establish that they fall outside a ban.
- The abstract confirms activity in an authentic sample and detection of tested substances with BTNX version 2.0 strips; it does not establish universal sensitivity in market samples.
A study published on August 18, 2026, in the journal Drug Testing and Analysis reports cell-based characterization of cyanazenes by Inez Lambrecht, Christophe Stove and Marthe Vandeputte. The study measures beta-arrestin 2 recruitment at the mu-opioid receptor, not clinical potency, toxicity or effects in people.
Structure and activity in the laboratory
The study compares four cyano-substituted derivatives with related compounds, addressing laboratory structure–activity relationships. The inspected abstract does not show that a ban caused their emergence or establish which substances fall outside a country’s controls.
What the New Study Shows
In this assay, 5-cyano isotodesnitazene showed lower potency than isotonitazene and fentanyl and comparable activity to isotodesnitazene. The other three cyanazenes showed similar trends: cyano substitution did not compensate for potency lost with removal of the nitro group. Maximum assay response is not clinical efficacy or lower danger. The abstract also reports activity in an authentic sample without detailing provenance here; this review did not read the cited detection study.
What It Implies
The researchers themselves insist that these are in vitro data, obtained in laboratory cells and not in people, and that the actual potency in the body also depends on how each substance is metabolized. But there is news of direct interest to those who use drugs or work in harm reduction: the tested substances were detectable with BTNX version 2.0 under laboratory conditions. This does not validate every strip version, concentration or mixture, or make a negative result a safety guarantee. Appropriate drug checking provides additional information without eliminating every sample risk.
Source
- Lambrecht, I. M., Stove, C. P., Vandeputte, M. M. “In Vitro Pharmacological Characterization of a Series of 5-Cyano Desnitazene Opioids or ‘Cyanazenes'”. Drug Testing and Analysis, August 18, 2026.
Educational content written from a harm reduction perspective and with respect for individual freedom. It is not a substitute for advice from a healthcare professional and is not intended to encourage or condemn any drug use.
